Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Delirium 2Recurrence 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Hematologic Neoplasms 1

Interventions

pembrolizumab 593Cyclophosphamide 539Magnetic Resonance Spectroscopy 527Radiotherapy 506Specimen Handling 504Nivolumab 406Cisplatin 370Carboplatin 360Biopsy 306Blood Specimen Collection 296Radiosurgery 284Paclitaxel 276Surveys and Questionnaires 269Standard of Care 267Gemcitabine 266fludarabine 261Dexamethasone 258Drug Therapy 256Bevacizumab 248venetoclax 247Oxaliplatin 206Rituximab 197Capecitabine 194Radiation 190Fluorouracil 186Ipilimumab 183durvalumab 181Doxorubicin 174atezolizumab 172Etoposide 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lorazepam × 1 year × Clear all
NCT01949662 2026-02-13

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
93 enrolled 14 charts
Other hematologic neoplasm

Delirium, Hematologic Neoplasms, Neurotoxicity Syndromes

NCT03743649 2025-12-26

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

M.D. Anderson Cancer Center

Phase 2/3 Active not recruiting
110 enrolled

Delirium, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡